Welcome to our dedicated page for Anixa Biosciences SEC filings (Ticker: ANIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anixa Biosciences, Inc. filings document regulatory disclosures for a cancer-focused biotechnology company developing vaccine and CAR-T therapy programs. Recent Form 8-K reports include Regulation FD disclosures on the company's ovarian cancer CAR-T program, lira-cel, and its investigational breast cancer vaccine, including related press releases and scientific-presentation exhibits.
The company's proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, common-stock voting results, and other governance matters. These filings provide the formal record for Anixa's public-company reporting around clinical-program updates, stockholder actions, and corporate oversight.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock in an open-market transaction on July 31, 2026, at $3.47 per share. After this purchase, he directly holds 657,000 shares of Anixa Biosciences common stock.
Arnold M. Baskies, a director of Anixa Biosciences Inc, exercised employee stock options covering 6,000 shares of common stock on July 27, 2026 at an exercise price of $3.1300 per share. These options were granted on August 23, 2013 and were approaching expiration on August 23, 2026.
To cover the option exercise cost, 5,428 shares of common stock were withheld by Anixa Biosciences Inc at $3.4600 per share. Following this exercise, the related stock option position reported for this grant was reduced to 0 derivative securities.
Amit Kumar, Chief Executive Officer and director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 27, 2026 in a transaction reported as a purchase in open market or private transaction at $3.44 per share, bringing his directly held stake to 652,000 shares.
Anixa Biosciences Inc reported that Chief Executive Officer Amit Kumar purchased 3,188 shares of Common Stock on July 27, 2026, at $3.37 per share in a purchase in open market or private transaction. Following this transaction, he directly holds 647,000 shares.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 3,000 shares of Common Stock on July 24, 2026 at $3.73 per share in an open-market or private transaction. Following this trade, his directly held position increased to 643,812 shares of Anixa Biosciences Inc common stock.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock on 2026-07-20 at $3.46 per share in an open-market or private transaction. Following this buy, he directly owns 640,812 shares. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.
Lewis H. Titterton Jr., a director of Anixa Biosciences Inc, purchased 12,000 shares of common stock on July 20, 2026 at $3.47 per share in a transaction classified as a purchase in open market or private transaction, bringing his direct holdings to 986,967 shares.
Lewis H. Titterton Jr., a director of Anixa Biosciences Inc (ANIX), reported an open-market purchase of 2,797 shares of common stock on July 15, 2026 at $3.28 per share. After this transaction, he directly holds 974,967 shares of Anixa common stock.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar reported an open-market purchase of 5,000 shares of Common Stock on July 10, 2026 at $3.04 per share. Following this transaction, he directly holds a total of 635,812 shares of Anixa Biosciences common stock.
Anixa Biosciences director Lewis H. Titterton Jr. bought 2,836 shares of Anixa Biosciences common stock in an open-market purchase at $2.64 per share. After this transaction, he directly holds 972,170 common shares, indicating a small incremental increase in his personal stake in the company.